The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:
generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer
* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
Follow-up data should be available
Patients with recurrent disease are allowed
None